The GLP-1 receptor agonist semaglutide reduces risks of kidney function loss, kidney failure, cardiovascular events, cardiovascular death and all-cause mortality in people with CKD and T2DM Ongoing clinical and mechanistic studies are expected to expand use of GLP-1 receptor agonists, GLP-1/GIP and other metabolic hormones for the treatment of CKD At the moment the most complete data is available for semaglutide from SUSTAIN-6 and FLOW trial which is the only trial with primary renal outcome in T2DM patients out of all GLP-1 RA Very good data for renal outcomes as secondary ones available for GLP-1 RAs dulaglutide and liraglutide and GLP-1/GIP RA tirzepatide, Very interesting and positive data from mechanistic REMODEL trial with semaglutide in T2DM patients presented but not yet published (reduced perirenal fat, rernal fibrosis and much more) Based on following excellent papers: #glp1 #gip #semaglutide #tirzepatide #liraglutide #dulaglutide #kidney #ckd #chronickidneydisease #cardiovascularcomplications To view or add a comment, sign in More Relevant Posts Just 1 year ago, semaglutide (Ozempic) was approved by the US Food and Drug Administration (FDA) for patients with chronic kidney disease (CKD) and type 2 diabetes (T2D)
GLP-1 Weight Loss Compounded Semaglutide Weight Loss Program The best-known weekly GLP-1 option for appetite control and durable weight-loss momentum
The Cleveland Clinic recommends aggressive hydration for patients on GLP-1 agonists
Non-Invasive Treatments: Advanced body contouring or similar non-invasive methods can complement weight-loss efforts for targeted results
all GLP-1 pricing is determined by the telehealth platform through which the prescription is placed
Generally, that means prioritizing whole foods, like fruit, vegetables, lean proteins, and whole grains, and limiting processed foods, pasta, and bread, says weight loss surgeon Nicholas Jones, MD, who also recommends having juices, sodas, and alcohol in moderation
